Enrollment will begin in January 2026Participants will be treated with buntanetap for 36 monthsThe study aims to enroll 500 ...

Cassava Sciences' phase 2 data was from a nonrandomized trial, therefore unconvincing. However, it indicated drug efficacy quite strongly. Phase 3 trial data will be major catalysts. Cassava Sciences ...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest clinical move targets a niche but ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Cassava Sciences, which spent 2022 trying to prove the integrity of its Alzheimer’s disease program, is trumpeting a phase 2 win for simufilam in an open-label study—but investors aren’t convinced.

CHICAGO--(BUSINESS WIRE)--An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of ...

Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer ...

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress. This is an ASCO Meeting ...

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Atai Beckley BPL-003 phase IIb open-label extension ...

Pacira ($PCRX) announced an update on their ongoing clinical study. Study Overview: Pacira Pharmaceuticals is running a Phase 2 trial titled “A ...